IRENE WILSON: Open Payments
NPI 1477021988 · SOUTHAVEN, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$484 in 25 payments from 10 companies in 2025. Trend: 2023 $1,137 · 2024 $356 · 2025 $484
Food & beverage: $484
| Company | Payments | Amount |
|---|---|---|
| Abbott Laboratories | 9 | $189 |
| Novo Nordisk Inc | 3 | $55 |
| AstraZeneca Pharmaceuticals LP | 3 | $54 |
| ABBVIE INC. | 2 | $47 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $38 |
| Esperion Therapeutics, Inc. | 2 | $28 |
| Corcept Therapeutics | 1 | $25 |
| GlaxoSmithKline, LLC. | 1 | $18 |
| SHIELD THERAPEUTICS INC | 1 | $16 |
| Amgen Inc. | 1 | $15 |
Products named: FREESTYLE LIBRE 3, Ozempic, NEXLETOL, QULIPTA, Korlym, FARXIGA, UBRELVY, JARDIANCE.
Industry payments across MS — which companies pay providers there.
